This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
arrhythmia yield versus 69.1% in daily-symptom patients, demonstrating that greater symptom frequenc y does not necessarily reflect increased arrhythmia burden. arrhythmia yield versus 69.1% in daily-symptom patients, demonstrating that greater symptom frequenc y does not necessarily reflect increased arrhythmia burden.
An international consensus statement on how to treat atrialfibrillation with catheter or surgical ablation has been published in EP Europace, a journal of the European Society of Cardiology (ESC), and was recently presented at EHRA 2024, a scientific congress held April 7-9 in Berlin, Germany.
Innovation in medical technology exists to improve patient outcomes, increase surgical efficiency and enhance patient safety. Infrequently, we see medical technology innovation of a paradigmatic nature that changes the way physicians approach disease states and dramatically improve results. So, again, innovation is great.
Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. Our mission to combat complex heart rhythm diseases relies on optimizing interoperability.
The Heart Rhythm Society (HRS) is preparing for HRX 2024, the third annual event of its kind, which will be held from September 5-7, 2024, in Atlanta, GA, gathering cardiovascular health innovators together to explore discoveries and advance partnerships between medicine and technology. On Thursday, Sept. On Thursday, Sept.
During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrialfibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTec h i , announced the submission of the VARIPULSE Platform for Premarket Approval Application (PMA) to the U.S. milla1cf Thu, 03/28/2024 - 07:28 March 28, 2024 — Biosense Webster, Inc., Food & Drug Administration ( FDA ).
milla1cf Fri, 02/02/2024 - 17:18 February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 with CardioLab EP Recording system, to help clinicians in the diagnosis and treatment of cardiac arrhythmias. million people in the United States by 2050 and 17.9 J Am Coll Cardiol.
tim.hodson Wed, 03/12/2025 - 15:36 Broward Health recently announced it is now offering the Farapulse Pulsed Field Ablation System to treat atrialfibrillation (A-Fib). This innovative treatment represents a significant advancement over traditional thermal ablation methods and provides a more effective solution for patients.
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi , announced the commencement of patient cases with the investigational Laminar Left Atrial Appendage Elimination (LAAX) System as part of its pivotal investigational device exemption (IDE) study. Jennifer Currin, Ph.D.,
Background Cryoballoon ablation (CBA) and laser balloon ablation (LBA) are two innovative ways for the treatment of atrialfibrillation (AF). This study aimed to evaluate the efficacy and safety of cryoballoon ablation and laser balloon ablation in patients with AF. LBA presented a lower acute PVI rate per patients (CBA 97.0%
Background Catheter ablation (CA) for symptomatic atrialfibrillation (AF) offers the best outcomes for patients. Results Our patient cohort was older, with higher BMI, greater CHA2DS2-VASc scores, and larger left atrial sizes compared to similar previously published cohorts, while gender balance and other characteristics were similar.
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi , revealed findings from a company-funded study of real-world data. AFib is the most common type of cardiac arrhythmia and affects more than 6 million people in the United States and nearly 38 million people worldwide.2,3 In: AF Symposium.;
CTA and the ACC recognize there is strong potential for cardiac monitoring (through Consumer Cardiovascular Technology Solutions) to help identify and screen patients with AtrialFibrillation (AFib) and related arrhythmias to alert the right clinical groups for early support and reduction in mortality rates.
The first procedures were performed by Dr. David Newton , Clinical Cardiac Electrophysiologist at Memorial Health University Physicians Heart Care and Dr. Andrea Natale , Executive Medical Director at T exas Cardiac Arrhythmia Institute, St. David’s Medical Center.
milla1cf Thu, 01/18/2024 - 14:21 January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed Field Ablation (PFA) System to treat patients battling common abnormal heart rhythms such as atrialfibrillation (AFib). chief medical officer of Abbott's electrophysiology business.
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech , today announced European CE mark approval of the VARIPULSE Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrialfibrillation ( AF ) using pulsed field ablation (PFA). AtrialFibrillation.
tim.hodson Wed, 03/12/2025 - 15:36 Broward Health recently announced it is now offering the Farapulse Pulsed Field Ablation System to treat atrialfibrillation (A-Fib). This innovative treatment represents a significant advancement over traditional thermal ablation methods and provides a more effective solution for patients.
Detection of Irregular Heart Rhythms Devices such as the Apple Watch or Fitbit Sense can detect irregular heart rhythms, including atrialfibrillation (AFib). By embracing this innovative approach, you can pave the way for a healthier heart and a brighter future.
At the forefront of PowerPlugs is AFib Detection , a PowerPlug that discreetly monitors your heart rhythm every night to detect signs of AtrialFibrillation (AFib). AFib is the most common type of irregular heart rhythm or arrhythmia. UltraSignal will help fuel more customization and innovation in health.
a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrialfibrillation, announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter.
As ECG Excellence we are proud our CineECG technology was part of this innovation festival. Their study focuses on the issue of localizing the origin of atrial ectopic activity. If you want to learn more go to : [link] and search for CineECG The post Origin of atrial ectopic activity appeared first on ECG-Excellence.
OSA is commonly seen in patients with arrhythmias like atrialfibrillation (AFib) and due to the variable unpredictable nature of sleep apnea symptoms, it is often untreated, leading to adverse outcomes. Peerbridge Health continues to innovate by compounding clinical utility in one simple device," said Andrea Natale, M.D.,
Director of Cardiac Arrhythmia Services for the Mount Sinai Health System in New York City. We will continue to fulfill our commitment to innovation, including new indications, to advance cardiovascular care and improve patient outcomes." tim.hodson Wed, 10/30/2024 - 13:42 Oct. The potential of Affera is limitless.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content